The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects

Hoyoung An, Booyeol Choi, Kun Woo Park, Do Hoon Kim, Dong Won Yang, Chang Hyung Hong, Seong Yoon Kim, Seol Heui Han

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Effective treatments to alleviate depression in Alzheimer's disease (AD) have been scarce. Objective: To investigate the efficacy and tolerability of escitalopram in the treatment of depression in AD. Methods: In this 12-week randomized, double-blind, placebo-controlled trial with open-label, 12-week extension, AD subjects over 50 years of age, with depression defined by Olin's provisional diagnostic criteria, were enrolled. The Cornell Scale for Depression in Dementia (CSDD), and other measures of depression and cognition were repeated. Results: 91 subjects were screened, and 84 were randomized into either the study group or placebo group (n = 42 for both groups). Twenty-four subjects (29) were unable to finish the study, yielding a per protocol population of 60 subjects (study group: n = 27; placebo group: n = 33). At week 12, differences in measures of depression and cognition between the two groups were not statistically significant. However, exploratory analysis suggested that further research on a subset of subjects with 'definite major depression' (baseline CSDD score ≥18) is needed. The number of treatment-related adverse-events (AE) did not differ between groups (p = 0.83) and no serious treatment-related AE were observed. Conclusion: The use of escitalopram was well tolerated in depressive dementia patients. Future studies focusing on subjects with more severe levels of depression, and with more statistical power, will be needed.

Original languageEnglish
Pages (from-to)727-735
Number of pages9
JournalJournal of Alzheimer's Disease
Volume55
Issue number2
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Citalopram
Cognition
Alzheimer Disease
Depression
Dementia
Placebos
Therapeutics

Keywords

  • Alzheimer's disease
  • clinical trial
  • depression
  • escitalopram
  • placebo

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects. / An, Hoyoung; Choi, Booyeol; Park, Kun Woo; Kim, Do Hoon; Yang, Dong Won; Hong, Chang Hyung; Kim, Seong Yoon; Han, Seol Heui.

In: Journal of Alzheimer's Disease, Vol. 55, No. 2, 01.01.2017, p. 727-735.

Research output: Contribution to journalArticle

An, Hoyoung ; Choi, Booyeol ; Park, Kun Woo ; Kim, Do Hoon ; Yang, Dong Won ; Hong, Chang Hyung ; Kim, Seong Yoon ; Han, Seol Heui. / The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects. In: Journal of Alzheimer's Disease. 2017 ; Vol. 55, No. 2. pp. 727-735.
@article{defd702b21cf4339995299dca1f7c6b9,
title = "The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects",
abstract = "Background: Effective treatments to alleviate depression in Alzheimer's disease (AD) have been scarce. Objective: To investigate the efficacy and tolerability of escitalopram in the treatment of depression in AD. Methods: In this 12-week randomized, double-blind, placebo-controlled trial with open-label, 12-week extension, AD subjects over 50 years of age, with depression defined by Olin's provisional diagnostic criteria, were enrolled. The Cornell Scale for Depression in Dementia (CSDD), and other measures of depression and cognition were repeated. Results: 91 subjects were screened, and 84 were randomized into either the study group or placebo group (n = 42 for both groups). Twenty-four subjects (29) were unable to finish the study, yielding a per protocol population of 60 subjects (study group: n = 27; placebo group: n = 33). At week 12, differences in measures of depression and cognition between the two groups were not statistically significant. However, exploratory analysis suggested that further research on a subset of subjects with 'definite major depression' (baseline CSDD score ≥18) is needed. The number of treatment-related adverse-events (AE) did not differ between groups (p = 0.83) and no serious treatment-related AE were observed. Conclusion: The use of escitalopram was well tolerated in depressive dementia patients. Future studies focusing on subjects with more severe levels of depression, and with more statistical power, will be needed.",
keywords = "Alzheimer's disease, clinical trial, depression, escitalopram, placebo",
author = "Hoyoung An and Booyeol Choi and Park, {Kun Woo} and Kim, {Do Hoon} and Yang, {Dong Won} and Hong, {Chang Hyung} and Kim, {Seong Yoon} and Han, {Seol Heui}",
year = "2017",
month = "1",
day = "1",
doi = "10.3233/JAD-160225",
language = "English",
volume = "55",
pages = "727--735",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects

AU - An, Hoyoung

AU - Choi, Booyeol

AU - Park, Kun Woo

AU - Kim, Do Hoon

AU - Yang, Dong Won

AU - Hong, Chang Hyung

AU - Kim, Seong Yoon

AU - Han, Seol Heui

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Effective treatments to alleviate depression in Alzheimer's disease (AD) have been scarce. Objective: To investigate the efficacy and tolerability of escitalopram in the treatment of depression in AD. Methods: In this 12-week randomized, double-blind, placebo-controlled trial with open-label, 12-week extension, AD subjects over 50 years of age, with depression defined by Olin's provisional diagnostic criteria, were enrolled. The Cornell Scale for Depression in Dementia (CSDD), and other measures of depression and cognition were repeated. Results: 91 subjects were screened, and 84 were randomized into either the study group or placebo group (n = 42 for both groups). Twenty-four subjects (29) were unable to finish the study, yielding a per protocol population of 60 subjects (study group: n = 27; placebo group: n = 33). At week 12, differences in measures of depression and cognition between the two groups were not statistically significant. However, exploratory analysis suggested that further research on a subset of subjects with 'definite major depression' (baseline CSDD score ≥18) is needed. The number of treatment-related adverse-events (AE) did not differ between groups (p = 0.83) and no serious treatment-related AE were observed. Conclusion: The use of escitalopram was well tolerated in depressive dementia patients. Future studies focusing on subjects with more severe levels of depression, and with more statistical power, will be needed.

AB - Background: Effective treatments to alleviate depression in Alzheimer's disease (AD) have been scarce. Objective: To investigate the efficacy and tolerability of escitalopram in the treatment of depression in AD. Methods: In this 12-week randomized, double-blind, placebo-controlled trial with open-label, 12-week extension, AD subjects over 50 years of age, with depression defined by Olin's provisional diagnostic criteria, were enrolled. The Cornell Scale for Depression in Dementia (CSDD), and other measures of depression and cognition were repeated. Results: 91 subjects were screened, and 84 were randomized into either the study group or placebo group (n = 42 for both groups). Twenty-four subjects (29) were unable to finish the study, yielding a per protocol population of 60 subjects (study group: n = 27; placebo group: n = 33). At week 12, differences in measures of depression and cognition between the two groups were not statistically significant. However, exploratory analysis suggested that further research on a subset of subjects with 'definite major depression' (baseline CSDD score ≥18) is needed. The number of treatment-related adverse-events (AE) did not differ between groups (p = 0.83) and no serious treatment-related AE were observed. Conclusion: The use of escitalopram was well tolerated in depressive dementia patients. Future studies focusing on subjects with more severe levels of depression, and with more statistical power, will be needed.

KW - Alzheimer's disease

KW - clinical trial

KW - depression

KW - escitalopram

KW - placebo

UR - http://www.scopus.com/inward/record.url?scp=84999274255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999274255&partnerID=8YFLogxK

U2 - 10.3233/JAD-160225

DO - 10.3233/JAD-160225

M3 - Article

C2 - 27716660

AN - SCOPUS:84999274255

VL - 55

SP - 727

EP - 735

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -